17:40 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal; cancer

INDICATION: Adenomatous polyps; colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting JAG1 could help treat familial adenomatous polyposis (FAP) and Notch 1-positive, MFNG-negative colorectal cancers. In Notch 1-positive tumor samples from 198 colorectal...
17:43 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, mouse and cell culture studies suggest inhibiting JAG1 could help treat lung cancer. In samples from non-small cell lung cancer (NSCLC) patients, endothelial cell levels of the Notch 3 ligand JAG1...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Jagged 1 (JAG1); JAG2

Inflammation INDICATION: Asthma Mouse studies suggest inhibiting JAG1 and JAG2 could help treat asthma. In mice, a combination of anti-JAG1 and anti-JAG2 mAbs increased the numbers of mucus-clearing ciliated cells in the lungs compared with an inactive...
08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Jagged 1 (JAG1)

Musculoskeletal disease INDICATION: Muscular dystrophy Dog and zebrafish studies suggest promoting JAG1 expression could help treat Duchenne muscular dystrophy (DMD). Muscle levels of JAG1 were higher in a genetic dog model of DMD protection than in an...
08:00 , Jan 7, 2016 |  BC Innovations  |  Translation in Brief

New beginnings

The idea of regenerating tissue in coronary arteries after heart disease or injury has been slow to take hold because, although it's well-established that cells from the epicardium give rise to the smooth muscle in...
08:00 , Jan 8, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Notch 1 (NOTCH1); jagged 1 (JAG1); jagged 2 (JAG2)

Cancer INDICATION: Cancer In vitro and mouse studies suggest inhibiting JAG-mediated NOTCH1 signaling could help treat cancer by inhibiting angiogenesis. In an in vitro angiogenesis assay, human endothelial cells expressing NOTCH1 decoy proteins that inhibited binding of...
07:00 , Apr 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lymphoma Jagged 1 (JAG1); notch 2 (NOTCH2); fibroblast growth factor 4 (FGF4); fibroblast growth factor receptor 1 (FGFR1;...
08:00 , Feb 28, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Jagged 1 (JAG1) Cell culture studies suggest blocking soluble JAG1 could help treat colorectal cancer...
00:27 , Aug 1, 2012 |  BC Extra  |  Financial News

CytomX raises $11M in series B extension

CytomX Therapeutics Inc. (South San Francisco, Calif.) raised $11 million in an extension of a series B round, bringing the total raised in the round to $41 million. New investor Canaan Partners led the extension...